NIH-funded research R21 grant

How a protein in immune cells may protect arteries from plaque

Official title: Role of PKC Epsilon in Atheroprotection

Funded at Albany Medical College · NIH-11294184 · Data updated 2026-11-12

Researchers are looking at whether a protein called PKC‑epsilon in immune cells helps calm artery inflammation and reduce plaque in people at risk for heart attacks and strokes.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionAlbany Medical College
NIH-funded
Lab location1 site (Albany, United States)
Project startMarch 1, 2025
Project endFebruary 28, 2027
Funding year2026
Award (this year)$205,000
NIH project number5R21AI185827-02
Project IDNIH-11294184 on NIH RePORTER

Who could benefit from this research

Could help

People with or at high risk for atherosclerotic cardiovascular disease (for example, high cholesterol or previous heart attack or stroke) would be the most relevant group for related future research.

Less likely to help

People without atherosclerosis or with health issues unrelated to artery plaque are unlikely to see direct benefit from this project.

What this research studies

The team uses specially bred mice that lack PKC‑epsilon only in their immune (myeloid) cells and puts them on a high‑cholesterol regimen to produce artery plaque, then compares those mice to normal mice. They measure plaque size and composition, immune cell activity in plaques, and levels of specialized pro‑resolving lipids that help turn off inflammation. By linking how immune cells process oxidized cholesterol to the production of these resolving signals, they aim to identify how PKC‑epsilon promotes healing of artery inflammation. Findings could point to new ways to promote inflammation resolution and reduce atherosclerosis.

Why it matters

Potential benefit: If successful, this work could reveal targets for therapies that boost the body's ability to resolve artery inflammation and reduce plaque, lowering risk of heart attacks and strokes.

How similar studies have gone: Preclinical animal studies have suggested PKC‑epsilon influences inflammation and plaque, but translating this mechanism into proven human treatments remains unproven.

Where this research is happening

  • Albany Medical College
    Albany, United States
    Active

Researchers

  • Principal investigator: Lennartz, Michelle R — Albany Medical College
  • Study coordinator: Lennartz, Michelle R

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.